Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Matrix Partners China
AddedFeb 13, 2024
UpdatedJul 16, 2026
Matrix Partners China

Matrix Partners China

Operating

Matrix Partners China: Structured growth investor fostering long-term entrepreneur relationships.

Location
Beijing, Beijing, CN
Founded
2008
Firm
Analysis
Compare
Portfolio
Employees
News
Website

Investments

Rgenta Therapeutics
Rgenta Therapeutics

Total Raised

$116.9M

Rounds

6

Series A$52MNovember 2022
Seed$20MApril 2020
vesoft
vesoft

Total Raised

$8M

Rounds

2

Series ASeptember 2022
Series A$8MJune 2020
Logseq
Logseq

Total Raised

$4.1M

Rounds

1

Seed$4.1MMay 2022
Bytebase
Bytebase

Total Raised

$3M

Rounds

1

Seed$3MNovember 2021
Collov
Collov

Total Raised

$21M

Rounds

3

Seed$8MOctober 2021
RootPath Genomics
RootPath Genomics

Total Raised

$68M

Rounds

3

Series B$50MSeptember 2021
Series A$11MJanuary 2020
PAQ Therapeutics
PAQ Therapeutics

Total Raised

$30M

Rounds

1

Series A$30MJuly 2021
Bito Robotics
Bito Robotics

Total Raised

$60M

Rounds

5

Series AJuly 2021
NiKang Therapeutics
NiKang Therapeutics

Total Raised

$260M

Rounds

3

Series C$200MMay 2021
Series B$50MSeptember 2020
TDengine
TDengine

Total Raised

$69M

Rounds

5

Series B$47MMay 2021
Edda Technology
Edda Technology

Total Raised

$150M

Rounds

1

Private Equity$150MApril 2021
Senti Biosciences
Senti Biosciences
Public

Total Raised

$215.9M

Rounds

11

Series B$105MJanuary 2021
Tallac Therapeutics
Tallac Therapeutics

Total Raised

$88.2M

Rounds

3

Series A$62MDecember 2020
Lumist
Lumist

Total Raised

$10M

Rounds

1

Series A$10MAugust 2020
Lightelligence
Lightelligence
Series Unknown

Total Raised

$36M

Rounds

4

Series A$26MApril 2020
Ansun Biopharma
Ansun Biopharma
Public

Total Raised

$213.1M

Rounds

7

Series B$100MOctober 2019
Series A$85MMay 2018
nice
nice

Total Raised

$64M

Rounds

4

Series DJune 2019
Li Auto
Li Auto
Public

Total Raised

$5.7B

Rounds

7

Series C$530MJune 2019
Chameleon Biosciences
Chameleon Biosciences

Total Raised

$14.2M

Rounds

5

Seed$3MMarch 2019
TokenInsight
TokenInsight

Total Raised

$2M

Rounds

3

Series A$2MOctober 2018